World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
52367
World Ranking
6685
National Ranking
382

Martin Dreyling publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Martin Dreyling sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 780 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Martin Dreyling D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Martin Dreyling sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Martin Dreyling is affiliated with Ludwig-Maximilians-Universität München in Germany. Their research focuses predominantly on medicine, with significant contributions in pathology and forensic medicine, oncology, genetics, immunology, and neurology.

Their main topics of work include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics

Martin Dreyling has published extensively across multiple venues, contributing notably to the following journals:

  • Blood
  • Hematological Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Journal of Clinical Oncology

They have collaborated frequently with several co-authors including Eva Hoster, Catherine Thiéblemont, Andreas Viardot, Stephen J. Schuster, and Christiane Pott.

Among their recent papers are:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study (2020, The Lancet Oncology)
  • Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial (2021, Nature Medicine)
  • CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma (2021, Blood)
  • Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma (2022, New England Journal of Medicine)

Best Publications

  • Revised response criteria for malignant lymphoma

    Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne

  • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

    Wolfgang Hiddemann;Michael Kneba;Martin Dreyling;Norbert Schmitz

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • The landscape of genomic alterations across childhood cancers

    Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  • The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

    Roswitha Forstpointner;Martin Dreyling;Roland Repp;Sandra Hermann

  • Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

    Georg Lenz;Martin Dreyling;Eva Hoster;Bernhard Wörmann

  • Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

    Martin Dreyling;Georg Lenz;Eva Hoster;Achiel Van Hoof

  • Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

    Alessandro Pastore;Vindi Jurinovic;Robert Kridel;Eva Hoster

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

    Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

  • Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Dreyling;M Ghielmini;S Rule;G Salles

  • Treatment of Older Patients with Mantle-Cell Lymphoma

    H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  • Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

    Annina Herrmann;Eva Hoster;Thomas Zwingers;Günter Brittinger

  • Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

    Martin Dreyling;Wojciech Jurczak;Mats Jerkeman;Rodrigo Santucci Silva

  • Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

    Patricia Pérez-Galán;Martin Dreyling;Adrian Wiestner

  • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma : A systematic review and meta-analysis

    Holger Schulz;Julia F. Bohlius;Sven Trelle;Nicole Skoetz

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

Frequent Co-Authors

Wolfgang Hiddemann
Wolfgang Hiddemann Ludwig-Maximilians-Universität München
Wolfram Klapper
Wolfram Klapper Kiel University
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Michael Hallek
Michael Hallek University of Cologne
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Andreas Rosenwald
Andreas Rosenwald University of Würzburg
Michael Kneba
Michael Kneba Kiel University
Michael Pfreundschuh
Michael Pfreundschuh Saarland University
Norbert Schmitz
Norbert Schmitz University of Münster

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary educational pathways can open doors to a wide range of healthcare careers in the USA. For nurses seeking advanced qualifications, there are options like a DNP program without clinical hours, which offers leadership-focused advancement while avoiding the time-intensive clinical requirements.

Those looking to enter the field quickly may consider a lpn program, often available online with accelerated timelines that make it feasible to start working as a Licensed Practical Nurse in less than a year.

Nursing professionals aiming to specialize in mental health can pursue accelerated msn psychiatric np programs, designed to fast-track certification for those wishing to work as Psychiatric Mental Health Nurse Practitioners.

Additionally, students interested in the operational side of healthcare can earn a bachelors in healthcare administration online, providing a flexible pathway into healthcare management, policy, and leadership roles, often at an affordable cost.

Best Scientists Citing Martin Dreyling

Trending Scientists

Recently Published Articles